Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease
Launched by INCYTE CORPORATION · Jun 16, 2023
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at patients who have recently received an allogeneic stem cell transplant (a procedure where stem cells from a donor are used to replace damaged cells in a patient) and are at risk for developing chronic graft-versus-host disease (cGVHD). cGVHD is a condition where the donated cells attack the patient's body, which can lead to various health issues. The study aims to gather information about these patients to better understand how to manage and prevent cGVHD.
To participate in this study, individuals must be at least 18 years old and have had their stem cell transplant between 90 and 180 days prior to joining the trial. There are no specific exclusions, so many patients may be eligible. Participants will be asked to complete questionnaires about their health, either on their own or with some help. This study is currently recruiting, and your involvement could contribute to important research that may help other patients in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18 years inclusive at the time of signing the ICF
- • Allogeneic SCT 90 to 180 days prior to enrollment
- • Able to comprehend and willing to provide informed consent
- • Willing and able to complete participant-assessment questionnaires either alone or with minimal assistance from a caregiver and/or trained site personnel
- Exclusion Criteria:
- • There are no exclusion criteria for this study
About Incyte Corporation
Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for oncology and other serious diseases. With a commitment to advancing precision medicine, Incyte leverages its expertise in molecular biology and clinical research to develop targeted treatments that address unmet medical needs. The company is dedicated to improving patient outcomes through rigorous clinical trials and collaborations with healthcare professionals and research institutions. Incyte's robust pipeline includes a range of investigational therapies aimed at various cancers, showcasing its dedication to transforming the landscape of cancer treatment.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Milwaukee, Wisconsin, United States
Rochester, Minnesota, United States
New York, New York, United States
Seattle, Washington, United States
Jacksonville, Florida, United States
New Orleans, Louisiana, United States
Duarte, California, United States
Birmingham, Alabama, United States
Atlanta, Georgia, United States
Orlando, Florida, United States
Nashville, Tennessee, United States
Baltimore, Maryland, United States
Chapel Hill, North Carolina, United States
Portland, Oregon, United States
Salt Lake City, Utah, United States
Los Angeles, California, United States
Phoenix, Arizona, United States
Charlotte, North Carolina, United States
Dallas, Texas, United States
Columbus, Ohio, United States
Fairway, Kansas, United States
Danville, Pennsylvania, United States
Grand Rapids, Michigan, United States
Boston, Massachusetts, United States
New Brunswick, New Jersey, United States
Aurora, Colorado, United States
Chicago, Illinois, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported